These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
766 related articles for article (PubMed ID: 29547706)
1. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Lim S; Eckel RH; Koh KK Atherosclerosis; 2018 May; 272():33-40. PubMed ID: 29547706 [TBL] [Abstract][Full Text] [Related]
2. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications. Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326 [TBL] [Abstract][Full Text] [Related]
3. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Kaul S Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Scheen AJ Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118 [TBL] [Abstract][Full Text] [Related]
6. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264 [TBL] [Abstract][Full Text] [Related]
7. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. Bonadonna RC; Borghi C; Consoli A; Volpe M Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139 [TBL] [Abstract][Full Text] [Related]
8. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770 [TBL] [Abstract][Full Text] [Related]
10. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits. Hupfeld C; Mudaliar S Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945 [TBL] [Abstract][Full Text] [Related]
11. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus. Shin JI Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon. Ren DY; Zhang Y Curr Drug Targets; 2018; 19(9):1051-1057. PubMed ID: 29848274 [TBL] [Abstract][Full Text] [Related]
15. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. Rahelić D; Javor E; Lucijanić T; Skelin M Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028 [TBL] [Abstract][Full Text] [Related]
16. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. Cruz JE; Ahuja T; Bridgeman MB Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393 [TBL] [Abstract][Full Text] [Related]
17. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996 [TBL] [Abstract][Full Text] [Related]
18. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective. Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613 [TBL] [Abstract][Full Text] [Related]
19. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury. Chu C; Lu YP; Yin L; Hocher B Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483 [TBL] [Abstract][Full Text] [Related]
20. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Trujillo JM; Nuffer WA Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]